KRAS and neoplasm: Bidard et al. conducted sub-analyses in the PRODIGE-14 trial, in which patients with CRLM ineligible for curative resection were allocated in chemotherapeutic treatment groups based on the KRAS exon 2 mutational status in their tumour tissue [26].